PharmAla completes release testing on LaNeo capsules

PharmAla (MDXXF) Biotech announces that it has completed release testing of its first Australian-made batch of LaNeo MDMA 40mg capsules. “PharmAla is pleased to have completed this first batch of material of Australian-made materials in partnership with our colleagues at Cortexa. This material will continue to drive progress in the Australian market, as well as our ongoing operations globally,” said Farnoud Kazemzadeh, COO, PharmAla Biotech. “However, we are all the more excited to move forward into a very active production schedule for 2026 – including the development and release of our 20mg capsules, and the manufacture and encapsulation of our first run of ALA-002 capsules.”